MedTrace Logo

Effect of Cabergoline on Weight and Glucose Tolerance

NCT01395602 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-10-14

No results posted yet for this study

Summary

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults.

This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks.

The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Conditions

  • Body Weight
  • Impaired Glucose Tolerance in Obese

Interventions

DRUG

Cabergoline

cabergoline 0.5 mg twice weekly

OTHER

placebo

1 pill twice weekly

Sponsors & Collaborators

Principal Investigators

  • Judith Korner, MD, PHD · Columbia University

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2003-09-30
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01395602 on ClinicalTrials.gov